A Phase 2, Double-blind Randomized, Sequential Treatment Group, Placebo-controlled Study To Evaluate The Safety, Tolerability And Brain Cortico-striatal Function Of 2 Doses Of Pf-02545920 In Subjects With Early Huntington's Disease
Phase of Trial: Phase II
Latest Information Update: 16 Dec 2017
At a glance
- Drugs Mardepodect (Primary)
- Indications Huntington's disease
- Focus Therapeutic Use
- Sponsors Pfizer
- 17 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Feb 2014 Planned number of patients changed from 65 to 56 as reported by ClinicalTrials.gov.
- 13 Feb 2014 Planned End Date changed from 1 Oct 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov.